Table 2 Clinicopathologic characteristics with respect to ERα protein and ESR1 mRNA expression in the p16+/HPV+ OPSCC group
Characteristics | ERα protein (n = 79) | ESR1 mRNA (n = 71) | ||||
|---|---|---|---|---|---|---|
Positive | Negative | p value | Positive | Negative | p value | |
Sex | ||||||
Male | 33 (91.7%) | 36 (83.7%) | 0.332 | 15 (100%) | 48 (85.7%) | 0.189 |
Female | 3 (8.3%) | 7 (16.3%) | 0 | 8 (14.3%) | ||
Age (years) | ||||||
< 65 | 25 (69.4%) | 30 (69.8%) | 1 | 12 (80%) | 37 (66.1%) | 0.363 |
≥ 65 | 11 (30.6%) | 13 (30.2%) | 3 (20%) | 19 (33.9%) | ||
Smoking history | ||||||
Never | 13 (36.1%) | 17 (39.5%) | 0.818 | 3 (20%) | 22 (39.3%) | 0.228 |
Ever | 23 (63.9%) | 26 (60.5%) | 12 (80%) | 34 (60.7%) | ||
Subsite | ||||||
Palatine tonsil | 31 (86.1%) | 37 (86%) | 0.589 | 13 (86.6%) | 47 (83.9%) | 0.886 |
Base of tongue | 4 (11.1%) | 3 (7%) | 1 (6.7%) | 6 (10.7%) | ||
Pharyngeal wall | 1 (2.8%) | 3 (7%) | 1 (6.7%) | 3 (5.4%) | ||
Sample type | ||||||
Biopsy specimen | 13 (36.1%) | 12 (27.9%) | 0.474 | 7 (46.7%) | 15 (25%) | 0.12 |
Resected specimen | 23 (63.9%) | 31 (72.1%) | 8 (53.3%) | 42 (75%) | ||
Surgical margina | ||||||
Clear | 19 (82.6%) | 20 (64.5%) | 0.255 | 6 (75%) | 30 (71.4%) | 1 |
Involved | 4 (17.4%) | 11 (35.5%) | 2 (25%) | 12 (28.6%) | ||
Lymphovascular invasiona | ||||||
Absent | 14 (60.9%) | 16 (51.6%) | 0.588 | 5 (62.5%) | 21 (50%) | 0.704 |
Present | 9 (39.1%) | 15 (48.4%) | 3 (37.5%) | 21 (50%) | ||
Perineural invasiona | ||||||
Absent | 22 (95.7%) | 28 (90.3%) | 0.563 | 8 (100%) | 38 (90.5%) | 1 |
Present | 1 (4.3%) | 3 (9.7%) | 0 | 4 (9.5%) | ||
Initial stage (8th AJCC) | ||||||
I | 22 (61.1%) | 24 (55.8%) | 0.062 | 7 (46.7%) | 34 (60.7%) | 0.125 |
II | 14 (38.9%) | 13 (30.2%) | 8 (53.3%) | 16 (28.6%) | ||
III | 0 | 6 (14%) | 0 | 6 (10.7%) | ||
HPV type | ||||||
Type 16 | 25 (69.4%) | 39 (90.7%) | 0.022* | 11 (73.3%) | 46 (82.1%) | 0.475 |
Type other than 16 | 11 (30.6%) | 4 (9.3%) | 4 (26.7%) | 10 (17.9%) | ||
Total | 36 (45.6%) | 43 (54.4%) | 15 (21.1%) | 56 (78.9%) | ||